enGene Therapeutics (ENGN) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on enGene Therapeutics (ENGN) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.37 bearish.

enGene Therapeutics last closed at $1.87, -3.61% on the session.

Against the IVW growth benchmark the position is -4.22% over the forecast window.

The read is built from 11 underlying insights — 0 bullish and 11 bearish.

Agreement across those insights is 100%.

16 graded predictions for ENGN so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks enGene Therapeutics in the 17th percentile on return on equity, where 100 is best.

enGene Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $125.32M.

StockMap tracks enGene Therapeutics as the 265th largest of the 365 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 190 Moderate Underperform, 164 Neutral and 11 Strong Underperform.

On that composite enGene Therapeutics ranks 305th of 365 in the group, against a group median of -0.21.